Small cell lung cancer (SCLC) is a fast-growing cancer that forms in the lung. It's one of two types of lung cancer. The other type is non-small cell lung cancer (NSCLC). SCLC is less common than ...

A targeted therapy called sevabertinib has been approved for patients with non-small cell lung cancer that carries an ...

(PTx) announced findings from a post hoc analysis of the eNRGy trial (NCT02912949) evaluating treatment beyond progression with zenocutuzumab in patients with advanced neuregulin 1 fusion-positive ...

Treatment with amivantamab is associated with a broad spectrum of dermatologic adverse events that can be severe in patients with non-small cell lung cancer, a real-world study shows.

Some six years after the FDA approved Eli Lilly’s Retevmo to treat lung a | Six years after the FDA approved Eli Lilly’s ...

A new randomized clinical trial showed that receiving immunochemotherapy infusions earlier in the day may help patients with ...

Researchers have identified a biological mechanism that helps explain why some lung and ovarian cancers become resistant to ...

HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...

Hernexeos (zongertinib) received FDA accelerated approval for unresectable or metastatic non-squamous NSCLC with HER2 TKD mutations after prior treatment. The Beamion LUNG-1 trial showed a 75% ...

Sunvozertinib is the first targeted oral treatment for NSCLC with EGFR exon 20 insertion mutations, approved for post-chemotherapy progression cases. The WU-KONG1 Part B study showed a 53.3% objective ...